- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02298998
Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention" refers to surveillance based on the EAU guidelines and the "control" refers to surveillance based on the AUA guidelines.
Research methods: Participants who presents with non-muscle invasive bladder cancer and meets the inclusion/exclusion criteria will be given an option to participate in the study. Participants will be enrolled at the Urology Clinics at the University of Texas Health Science Center San Antonio (UTHSCSA) Medical Arts and Research Center (MARC) and South Texas Veterans Health Care System (STVHCS). Non-local site include the University of Texas Southwestern Medical Center (UTSW). The research procedures consist of urine collection, cystoscopy, and patient satisfaction and cost questionnaires. The evaluation will be done by the tumor recurrence and progression of the disease. At various time points throughout the study, urine may be obtained from the patient and banked in the Genitourinary (GU) Tissue Bank. Subjects asked to provide a urine sample(s) will be asked to sign a separate informed consent. The urine is de-identified in the lab per the Health Insurance Portability and Accountability Act (HIPAA) protocol GU Tissue Bank Institutional Review Board (IRB) # 20050234H). Patients will undergo cystoscopy in clinic (standard of care). In the intervention arm, patient surveillance cystoscopy will be performed at 3, 12 months and again at 24 months following the diagnosis of bladder cancer. Patients randomized to the control arm, will undergo surveillance cystoscopy every 3 months for 2 years following the diagnosis of bladder cancer. Because use of cytology is variable among the participating urologist, the utilization of cytology will be at the treating urologist's discretion as per usual standard care. Study duration will be 2 years from most recent biopsy. Patients will be placed on the surveillance schedule based on the length of time from their last tumor.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Texas
-
San Antonio, Texas, Vereinigte Staaten, 78229
- The University of Texas Health Science Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Must have non-muscle invasive low-grade, papillary (Ta) bladder cancer.
- Must have a negative cystoscopy following most recent biopsy.
- Must be able to give informed consent.
- Must be age 18 or older.
- Must be at low- or low-intermediate risk for disease recurrence and progression according to the EAU guidelines.
Exclusion Criteria:
- Have a history of invasive (>=T1) bladder cancer.
- Have a history of carcinoma-in-situ (CIS).
- Unable to give informed consent.
- < 18 or younger.
- Variant histology (micropapillary, nested variant, non-urothelial cell carcinoma elements).
- Had a surveillance cystoscopy following most recent biopsy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Intervention
The intervention group refers to surveillance based on the EAU guidelines.
|
Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
Andere Namen:
|
Control
The control group refers to surveillance based on the AUA guidelines.
|
Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Demonstrate feasibility of study recruitment and retention in order to help plan for subsequent phase III study.
Zeitfenster: 2 years
|
2 years
|
Develop methods for assessing patient satisfaction and costs associated with cystoscopy during bladder cancer surveillance.
Zeitfenster: 2 years
|
2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Capture preliminary data regarding number of procedures and direct and indirect cost differences between study arms.
Zeitfenster: 2 years
|
2 years
|
Compare proportion of patients experiencing disease progression and recurrence at 2 years following most recent biopsy under two different surveillance approaches.
Zeitfenster: 2 years
|
2 years
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HSC20130177H
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Intervention
-
University of FloridaAbgeschlossenEmpfindlichkeitVereinigte Staaten
-
Case Western Reserve UniversityAmerican University; Purdue UniversityRekrutierung
-
Thomas Jefferson UniversityRekrutierungProstatakarzinomVereinigte Staaten
-
Rabin Medical CenterAcademic College of Tel Aviv-Jaffa; Israel Cancer AssociationUnbekanntEierstockkrebs | Krebs des Gebärmutterhalses | Krebs des EndometriumsIsrael
-
University of Kansas Medical CenterAbgeschlossen
-
Biolux Research Holdings, Inc.BeendetKieferorthopädische ZahnbewegungKanada
-
German Institute of Human NutritionBeneo GmbHAbgeschlossenDiabetes mellitus, Typ 2 | Metabolisches SyndromDeutschland
-
University MariborAktiv, nicht rekrutierendHerzkrankheiten | Herz-Kreislauf-Erkrankungen | Koronare Herzkrankheit | Koronare Herzerkrankung | Lebensstil | Kontinuierliche Glukoseüberwachung | Verhaltensänderung | CGM | Visuelle AnalyseSlowenien
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)AbgeschlossenHIV | Sexuell übertragbare InfektionenVereinigte Staaten
-
University of WashingtonNational Cancer Institute (NCI)AbgeschlossenMelanom | Lymphom | Gebärmutterhalskrebs | Leukämie | Brustkrebs | Darmkrebs | Darmkrebs | Bösartige NeubildungVereinigte Staaten